	HOME
»	WHAT IS ULCERATIVE COLITIS? ULCERATIVE COLITIS SYMPTOMS ULCERATIVE COLITIS RISK FACTORS ULCERATIVE COLITIS TREATMENT APRISO FAQ
	ABOUT APRISO
	WORKING WITH YOUR DOCTOR
	LIVING WITH UC
	SIGN UP FOR UC INFORMATION
	SIGN UP FOR APRISO SAVINGS

PRESCRIBING INFORMATION

FOR HEALTHCARE PROFESSIONALS

UC Symptoms

Which ones get in the way of your life?

An evening out with friends. A long, leisurely dinner with someone special. Saturday night at the movies. These are activities you should be able to enjoy any time. But, your ulcerative colitis (UC) symptoms may get in the way.

As you know, the most common symptoms are:

Diarrhea
Rectal bleeding
Stomach pain
Cramping
Frequent, urgent need to use bathroom
Fatigue

And they can lead to other complications, including:

Anemia
Depression

More severe UC symptoms include:

Fever
Weight loss
Nausea

The features of APRISO for UC patients.

There is no cure for UC. In fact, between 25-40 percent of patients develop severe UC symptoms, eventually requiring surgery. But managing symptoms — and preventing them from worsening — is a reasonable, attainable goal. APRISO can help.

APRISO is a once-daily 5-ASA that features INTELLICOR™ delayed- and extended-release delivery — for the successful long-term (6 months) management of ulcerative colitis (UC).

Being proactive about managing your symptoms is the best way to keep them from worsening. Don't let yourself be among the 40 percent of UC sufferers who report that they experience symptoms at least 180 days a year, according to The Voices of UC Survey, conducted on behalf of the Crohn's & Colitis Foundation of America.

In contrast, APRISO has been shown to be effective at helping people with UC stay in remission for up to six months. That's 180 days symptom free. Talk to your doctor about APRISO today.

Please see accompanying full Prescribing Information.

APRISO is a locally acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older. APRISO is contraindicated in patients with hypersensitivity to salicylates or aminosalicylates (sulfasalazine) or to any of the components of APRISO capsules. It is recommended that patients have an evaluation of renal function prior to initiation of APRISO therapy and periodically while on therapy. Exercise caution when using APRISO in patients with known renal dysfunction or a history of renal disease. There have been reports of hepatic failure in patients with pre–existing liver disease who have been administered mesalamine. Caution should be exercised when administering APRISO to patients with liver disease. The recommended dose of APRISO is four 0.375–g capsules once daily in the morning (1.5 g/day) with or without food. Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be coadministered with antacids. Patients with phenylketonuria should be aware that APRISO contains aspartame, equivalent to 2.24 mg of phenylalanine per day. In 2 well–controlled clinical trials, the most common treatment–related adverse events occurring in at least 3% of adult patients taking 1.5 g/day of APRISO were headache (11% vs 8% for placebo), diarrhea (8% vs 7% for placebo), upper abdominal pain (5% vs 3% for placebo), nausea (4% vs 3% for placebo), nasopharyngitis (4% vs 3% for placebo), influenza and influenza–like illness (4% vs 4% for placebo), and sinusitis (3% vs 3% for placebo).

For complete Prescribing Information, please click here.